Results 11 to 20 of about 170,488 (349)
Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants [PDF]
Haematologica, 2015 Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia results in resistance to p53-dependent apoptosis and inferior responses to treatment with DNA damaging agents. Hence, p53-independent strategies are required to target
Angelo Agathanggelou +20 more
doaj +6 more sources
The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax [PDF]
Haematologica, 2017 Fluorizoline is a new synthetic molecule that induces apoptosis by selectively targeting prohibitins. In the study herein, the pro-apoptotic effect of fluorizoline was assessed in 34 primary samples from patients with chronic lymphocytic leukemia ...
Ana M. Cosialls +12 more
doaj +3 more sources
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia [PDF]
Haematologica, 2015 Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The specific mechanism of action is still undefined, but includes modulation of the microenvironment.
Stefania Fiorcari +11 more
doaj +3 more sources
Chronic Lymphocytic Leukemia [PDF]
Cancers, 2020 This Special Issue of Cancers, made up of nine articles (four original papers, four reviews, and a brief report), is dedicated to chronic lymphocytic leukemia (CLL) [...]
Vaisitti T., Arruga F., Ferrajoli A.
openaire +6 more sources
Chronic lymphocytic leukemia [PDF]
Current Opinion in Hematology, 1999 Significant strides have been made in our understanding of the biology and treatment of B cell chronic lymphocytic leukemia. Recent studies have defined cytogenetic and molecular lesions that may be responsible for leukemogenesis or disease progression.
W G, Wierda, T J, Kipps
openaire +4 more sources
Frontiers in Immunology, 2022 Limited data are available about the underlying causes of hemophagocytic lymphohistiocytosis (HLH) in adults. We collected and analyzed the data of 555 cases of adult HLH.
Yi Miao +30 more
doaj +1 more source
Frontiers in Immunology, 2022 Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world with great heterogeneity. Pyroptosis has recently been recognized as an inflammatory form of programmed cell death (PCD) and shares a close relationship with apoptosis ...
Yeqin Sha +36 more
doaj +1 more source
Targeting Bruton’s Tyrosine Kinase in CLL
Frontiers in Immunology, 2021 Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj +1 more source
AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression
Frontiers in Oncology, 2021 The enzyme activation-induced cytidine deaminase (AID) initiates somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin (Ig) genes, critical actions for an effective adaptive immune response.
Pablo Oppezzo +2 more
doaj +1 more source
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Frontiers in Oncology, 2021 Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small ...
Susan M. O’Brien +6 more
doaj +1 more source